Andrew H. Limper

20.9k citations
291 papers · 14.5k · 5 hit papers · h-index 61

Impact in

    • Antifungal resistance and susceptibility
    • Tuberculosis Research and Epidemiology
    • HIV/AIDS drug development and treatment
  • Epidemiology top 0.1%
    • Pneumocystis jirovecii pneumonia detection and treatment
    • Pneumonia and Respiratory Infections
    • Fungal Infections and Studies

Papers in

    • Pneumocystis jirovecii pneumonia detection and treatment 150
    • Pneumonia and Respiratory Infections 53
    • Fungal Infections and Studies 22
    • Antifungal resistance and susceptibility 45
    • Tuberculosis Research and Epidemiology 30
    • HIV/AIDS drug development and treatment 27

Andrew H. Limper

283 papers receiving 14.2k citations

Andrew H. Limper's Hit Papers

Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability 2023 · 159 citations
1590+11+23Years since publication200400600

Peers

Andrew H. Limper
Comparison fields: 5 of 160
  • Infectious Diseases 3.7k
  • Epidemiology 6.1k
  • Pulmonary and Respiratory Medicine 4.3k
  • Immunology 1.3k
  • Physiology 1.5k
Replace Joseph P. Lynch with:
Joseph P. Lynch United States
O Jung Kwon South Korea
Jeffrey L. Curtis United States
Theodore J. Standiford United States
John J. Fung United States
Ritesh Agarwal India
Galen B. Toews United States
Edward D. Chan United States
Michael Tamm Switzerland
Stefan Zeuzem Germany
Andrew H. Limper relative to Joseph P. Lynch United States Joseph P. Lynch's profile →
Citations per field
00.5×2.8×
Joseph P. Lynch · 1×
Citations per year

Countries citing papers authored by Andrew H. Limper

Since Specialization
Citations

This map shows the geographic impact of Andrew H. Limper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew H. Limper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew H. Limper more than expected).

Fields of papers citing papers by Andrew H. Limper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew H. Limper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew H. Limper. The network helps show where Andrew H. Limper may publish in the future.

Co-authors

The 25 scholars most cited alongside Andrew H. Limper, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andrew H. Limper Line = papers co-authored together Andrew H. Limper links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 291 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pneumocystis Pneumonia
Hit paper breakdown →
2004716
2
Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.
Hit paper breakdown →
1991692
3
Pneumocystis carinii Pneumonia in Patients Without Acquired Immunodeficiency Syndrome: Associated Illnesses and Prior Corticosteroid Therapy
Hit paper breakdown →
1996464
4 2004443
5 2004410
6 2010407
7 1989385
8
Fungal infections in HIV/AIDS
Hit paper breakdown →
2017332
9 1999296
10 2000295
11 1990294
12 2009282
13 2002268
14 2003268
15 2017219
16 2007189
17 2005188
18
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
Hit paper breakdown →
2023159
19 1997151
20 2005144

About Andrew H. Limper

Andrew H. Limper is a scholar working on Epidemiology, Infectious Diseases, Pulmonary and Respiratory Medicine, Oncology and Organic Chemistry, having authored 291 papers that have together received 14.5k indexed citations. Recurring topics across this work include Pneumocystis jirovecii pneumonia detection and treatment (150 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (61 papers), Pneumonia and Respiratory Infections (53 papers), Antifungal resistance and susceptibility (45 papers), Peptidase Inhibition and Analysis (35 papers), Tuberculosis Research and Epidemiology (30 papers), HIV/AIDS drug development and treatment (27 papers) and Fungal Infections and Studies (22 papers). The work is most often cited by research in Infectious Diseases (3.7k citations), Epidemiology (6.1k citations), Pulmonary and Respiratory Medicine (4.3k citations), Immunology (1.3k citations) and Physiology (1.5k citations). Andrew H. Limper has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include Charles F. Thomas, Joseph E. Standing, Thomas V. Colby, Theodore J. Kottom, Robert Vassallo, Eva M. Carmona, Steven H. Yale, Edward B. Leof, Jay H. Ryu and Craig Daniels. Their work appears in journals such as CHEST Journal, Infection and Immunity, American Journal of Respiratory Cell and Molecular Biology, American Journal of Respiratory and Critical Care Medicine and The Journal of Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact